NASDAQ:OPGN - OpGen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.65
  • Forecasted Upside: 146.72 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.29
▼ -0.08 (-3.38%)
1 month | 3 months | 12 months
Get New OpGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.65
▲ +146.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OpGen in the last 3 months. The average price target is $5.65, with a high forecast of $5.65 and a low forecast of $5.65. The average price target represents a 146.72% upside from the last price of $2.29.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in OpGen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020Alliance Global PartnersBoost Price TargetBuy$5.00 ➝ $5.65Low
i
Rating by Ben Haynor at Alliance Global Partners
10/19/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by Y. Chen at HC Wainwright
6/9/2020Alliance Global PartnersReiterated RatingBuy$5.00High
i
Rating by Ben Haynor at Alliance Global Partners
9/9/2019AegisSet Price TargetBuy$20.00Low
i
Rating by Nathan Weinstein at Aegis
5/19/2019HC WainwrightReiterated RatingBuy$1.50High
i
Rating by Ram Selvaraju at HC Wainwright
3/1/2019Alliance Global PartnersInitiated CoverageBuy$2.30Medium
i
12/5/2018HC WainwrightSet Price TargetBuy$6.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/14/2018HC WainwrightSet Price TargetBuy$6.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/7/2018HC WainwrightSet Price TargetBuy$6.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/1/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/3/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/9/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/25/2018HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/5/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/16/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$9.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/8/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/24/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by R. Selvaraju at HC Wainwright
9/11/2017HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/9/2017HC WainwrightSet Price TargetBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/18/2017HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/19/2017Dawson JamesReiterated RatingBuyLow
i
Rating by R. Wasserman at Dawson James
2/28/2017HC WainwrightReiterated RatingBuy$50.00N/A
i
8/10/2016Rodman & RenshawSet Price TargetBuy$82.50N/A
i
Rating by yi chen at Rodman & Renshaw
6/29/2016Rodman & RenshawInitiated CoverageBuy$62.50N/A
i
(Data available from 2/28/2016 forward)
OpGen logo
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $2.29
$2.21
$2.46

50 Day Range

MA: $2.48
$2.06
$3.55

52 Week Range

Now: $2.29
$1.52
$5.76

Volume

1,632,455 shs

Average Volume

4,380,719 shs

Market Capitalization

$51.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OpGen?

The following sell-side analysts have issued reports on OpGen in the last twelve months: Alliance Global Partners, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for OPGN.

What is the current price target for OpGen?

1 Wall Street analysts have set twelve-month price targets for OpGen in the last year. Their average twelve-month price target is $5.65, suggesting a possible upside of 146.7%. Alliance Global Partners has the highest price target set, predicting OPGN will reach $5.65 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $5.65 for OpGen in the next year.
View the latest price targets for OPGN.

What is the current consensus analyst rating for OpGen?

OpGen currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPGN will outperform the market and that investors should add to their positions of OpGen.
View the latest ratings for OPGN.

What other companies compete with OpGen?

How do I contact OpGen's investor relations team?

OpGen's physical mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company's listed phone number is (301) 869-9683 and its investor relations email address is [email protected] The official website for OpGen is www.opgen.com.